LPL Financial
VYNE icon

LPL Financial’s VYNE Therapeutics VYNE Stock Holding History

LPL Financial’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-940
Closed -$2.54K – 4600
2022
Q4 		$2.54K Sell
940
-22
-2% -$88 ﹤0.01% 4448
2022
Q3 		$4K Hold
962
– – ﹤0.01% 4401
2022
Q2 		$7K Sell
962
-41
-4% -$344 ﹤0.01% 4395
2022
Q1 		$12K Hold
1,003
– – ﹤0.01% 4151
2021
Q4 		$18K Sell
1,003
-1
-0.1% -$21 ﹤0.01% 4296
2021
Q3 		$25K Buy
1,004
+153
+18% +$5.93K ﹤0.01% 4277
2021
Q2 		$54K Buy
851
+41
+5% +$3.25K ﹤0.01% 4132
2021
Q1 		$100K Buy
+810
New +$117K ﹤0.01% 3928

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

LPL Financial's VYNE Position: Q1 2023 in Review

LPL Financial sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 940 shares — an estimated $2.54K sold.

LPL Financial first reported a position in VYNE in Q1 2021 and held it in 8 quarters. The position peaked at $100K in Q1 2021. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • LPL Financial reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • LPL Financial sold 940 VYNE Therapeutics shares in Q1 2023, an estimated $2.54K.
  • LPL Financial first reported a position in VYNE Therapeutics in Q1 2021 and held it in 8 quarters.
  • LPL Financial's VYNE Therapeutics position peaked at $100K in Q1 2021.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on LPL Financial's 13F filing for Q1 2023, filed 10 May 2023.